No price history available.
Key financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CNYm | 20,680 | 20,549 | 22,338 | 24,525 | 25,435 | 23,962 | N/A | N/A |
| Operating profit | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | CNYm | 1,006 | 1,317 | 2,484 | 2,134 | 1,330 | 1,855 | N/A | N/A |
| EPS reported | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Humanwell Healthcare (Group) Co.,Ltd. operates internationally, delivering a wide spectrum of healthcare solutions across regions including the Asia Pacific, North America, and Africa. The company's diverse product range features pharmaceuticals for pain management, such as anesthetics and analgesics, alongside a significant focus on women's health, providing items for reproductive planning, emergency contraception, and general wellness. They also produce central nervous system (CNS) medications addressing conditions like bronchitis, migraines, dysmenorrhea, neuralgia, epilepsy, acute and chronic cerebrovascular diseases, brain injuries, and peripheral vascular disorders. Furthermore, their offerings extend to traditional herbal remedies for common ailments such as colds and flu, rheumatoid arthritis, dermatological concerns, hepatitis, urinary tract infections, and memory impairment. Humanwell also supplies anti-infective agents, a variety of over-the-counter (OTC) drugs for digestive complaints, cold and flu relief, anti-inflammatory purposes, infections, and nutritional supplements. Complementing these, they offer specific treatments aimed at cardiovascular, gastrointestinal, and reproductive system diseases. Established in Wuhan, China, in 1993, the enterprise was initially known as Wuhan Humanwell Healthcare (Group) Co., Ltd. before adopting its current name, Humanwell Healthcare (Group) Co.,Ltd., in March 2013.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Humanwell Healthcare (Group) Co.,Ltd. (600079.SS)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Humanwell Healthcare (Group) Co.,Ltd. operates internationally, delivering a wide spectrum of healthcare solutions across regions including the Asia Pacific, North America, and Africa. The company's diverse product range features pharmaceuticals for pain management, such as anesthetics and analgesics, alongside a significant focus on women's health, providing items for reproductive planning, emergency contraception, and general wellness. They also produce central nervous system (CNS) medications addressing conditions like bronchitis, migraines, dysmenorrhea, neuralgia, epilepsy, acute and chronic cerebrovascular diseases, brain injuries, and peripheral vascular disorders. Furthermore, their offerings extend to traditional herbal remedies for common ailments such as colds and flu, rheumatoid arthritis, dermatological concerns, hepatitis, urinary tract infections, and memory impairment. Humanwell also supplies anti-infective agents, a variety of over-the-counter (OTC) drugs for digestive complaints, cold and flu relief, anti-inflammatory purposes, infections, and nutritional supplements. Complementing these, they offer specific treatments aimed at cardiovascular, gastrointestinal, and reproductive system diseases. Established in Wuhan, China, in 1993, the enterprise was initially known as Wuhan Humanwell Healthcare (Group) Co., Ltd. before adopting its current name, Humanwell Healthcare (Group) Co.,Ltd., in March 2013.